ENOV logo

Enovis Corporation (ENOV)

$27.92

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ENOV

Market cap

$1.61B

EPS

-9.25

P/E ratio

--

Price to sales

0.44

Dividend yield

--

Beta

1.170664

Price on ENOV

Previous close

$27.68

Today's open

$27.99

Day's range

$27.55 - $28.37

52 week range

$16.70 - $31.67

Profile about ENOV

CEO

Damien McDonald

Employees

7802

Headquarters

Lewisville, TX

Exchange

New York Stock Exchange

Shares outstanding

57694806

Issue type

Common Stock

ENOV industries and sectors

Healthcare

Medical Equipment & Supplies

News on ENOV

Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London

Dallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT (6:30 a.m. ET).

news source

GlobeNewsWire • Nov 12, 2026

news preview

What Enovis (ENOV) Said on Its Q3 Earnings Call

Enovis NYSE: ENOV reported third-quarter sales of $559 million and raised its full-year adjusted earnings outlook, as growth in its reconstructive business and improved cash generation helped offset what executives described as a volatile market for medical procedures.

news source

MarketBeat • Nov 7, 2026

news preview

Enovis Corporation (ENOV) Q3 2026 Earnings Call Transcript

Enovis Corporation ( ENOV ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Ross Osborn - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vikramjeet Chopra - BMO Capital Markets Equity Research Steven Lichtman - William Blair & Company L.L.C.

news source

Seeking Alpha • Nov 6, 2026

news preview

ENOVIS Announces Third Quarter 2026 Results

Dallas, TX, Nov. 05, 2026 (GLOBE NEWSWIRE) -- - Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates

Enovis (ENOV) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.

news source

GlobeNewsWire • Oct 8, 2026

news preview

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.

news source

PRNewsWire • Sep 22, 2026

news preview

Insider at Medical Device Maker Buys More Than 7,500 Shares

The acquisition involved 7,598 shares at a weighted average price of $19.74 per share, representing a total investment of ~$150,000. The transaction size equals 14% of the equity stake held by the executive before the filing.

news source

The Motley Fool • Sep 14, 2026

news preview

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

news source

Zacks Investment Research • Sep 3, 2026

news preview

What Makes Enovis (ENOV) a New Buy Stock

Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Sep 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Enovis Corporation

Open an M1 investment account to buy and sell Enovis Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ENOV on M1